For research use only. Not for therapeutic Use.
HRX215 is a first-in-class, potent, selective and orally active MKK4 inhibitor with an IC50 value of 0.02 µM. HRX215 boosted liver regeneration and prevented liver failure after extensive hepatectomy in pigs. KEYWORDS: HRX215 | Supplier | MKK4 inhibitor | LN3348 | Darizmetinib | HRX 215 | HRX-215 | LN 3348 | LN-3348 | HRX 0215 | HRX0215 | HRX-0215 | CAS [2369583-33-3] | MAPK | Inhibitor | Enzymes | Liver regeneration | MAP2K
| Catalog Number | I047735 |
| CAS Number | 2369583-33-3 |
| Molecular Formula | C21H17F2N5O3S |
| Purity | ≥95% |
| IUPAC Name | N-[2,6-difluoro-3-(5-pyridin-4-yl-2H-pyrazolo[3,4-b]pyridine-3-carbonyl)phenyl]propane-1-sulfonamide |
| InChI | InChI=1S/C21H17F2N5O3S/c1-2-9-32(30,31)28-19-16(22)4-3-14(17(19)23)20(29)18-15-10-13(11-25-21(15)27-26-18)12-5-7-24-8-6-12/h3-8,10-11,28H,2,9H2,1H3,(H,25,26,27) |
| SMILES | CCCS(=O)(=O)NC1=C(C=CC(=C1F)C(=O)C2=C3C=C(C=NC3=NN2)C4=CC=NC=C4)F |
| Reference | S Zwirner et al. First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell. 2024 Mar 28;187(7):1666-1684. |
